Mylan Recalls Cytarabine Injection Vials Due to Particulate Matter
Mylan Institutional LLC is recalling 8,340 vials of Cytarabine Injection due to the presence of particulate matter. The affected product was distributed nationwide.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class I, which indicates a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. Per the rubric, FDA Class I recalls are assigned a score of 4 or higher.
Plain-English summary
Mylan Institutional LLC is recalling 8,340 vials of Cytarabine Injection 100 mg/5 mL (20 mg/mL), 5 mL Single-Dose Vial (NDC 0069-0152-01), packaged in 10 x 5 mL Vials per carton (NDC 0069-0152-02). The recall is being conducted due to the presence of particulate matter in the product.
The affected product is identified by Lot # 7801050 and has an expiration date of 05/2015. The product is distributed by Pfizer Labs, Division of Pfizer Inc., and was available nationwide. It is a prescription-only medication.
Healthcare providers and patients should stop using the affected vials and contact their pharmacist or the recalling firm for further instructions. Consumers should not use the product if they have any questions regarding its safety.
The recalled product
- Product
- Cytarabine Injection 100 mg/5 mL (20 mg/mL), 5 mL Single-Dose Vial (NDC 0069-0152-01), packaged in 10 x 5 mL Vials per carton (NDC 0069-0152-02), Rx only, Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY 10017.
- Manufacturer
- Mylan Institutional LLC
- Category
- Drug — Antineoplastic
- Hazard
- Affected units
- 8,340
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 7801050
- Exp. Date. 05/2015
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Mylan Institutional LLC
See all →- LowThiamine HCl Injection Recall: Vials with Incorrect Lot Numbers
FDA (Drugs) · 2021-06-09
- CriticalMylan Recalls Amiodarone Hydrochloride Injection Due to Labeling Mix-Up
FDA (Drugs) · 2020-09-09
- CriticalMylan Recalls Tranexamic Acid Injection Due to Labeling Mix-Up
FDA (Drugs) · 2020-09-09
- SevereMylan Recalls Daptomycin Injection Due to Particulate Matter
FDA (Drugs) · 2020-08-12
- ModerateMylan Recalls Aloprim Injection Vials Due to Discoloration
FDA (Drugs) · 2020-05-27
Same hazard · particulate matter
See all →- SevereACTHAR Gel Recalled for Presence of Glass and Stopper Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- CriticalAmerican Regent Recalls Papaverine Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Nitroglycerin Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Cyanocobalamin Injections Due to Particulate Matter
FDA (Drugs) · 2026-08-26